• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

机器学习预测结肠癌复发。

Machine learning for predicting colon cancer recurrence.

机构信息

Department of Medical Oncology, Suleyman Demirel University, Isparta, Turkey.

Department of Medical Oncology, Health Sciences University Antalya Research and Training Hospital, Antalya, Turkey.

出版信息

Surg Oncol. 2024 Jun;54:102079. doi: 10.1016/j.suronc.2024.102079. Epub 2024 Apr 19.

DOI:10.1016/j.suronc.2024.102079
PMID:38688191
Abstract

INTRODUCTION

Colorectal cancer (CRC) is a global public health concern, ranking among the most commonly diagnosed malignancies worldwide. Despite advancements in treatment modalities, the specter of CRC recurrence remains a significant challenge, demanding innovative solutions for early detection and intervention. The integration of machine learning into oncology offers a promising avenue to address this issue, providing data-driven insights and personalized care.

METHODS

This retrospective study analyzed data from 396 patients who underwent surgical procedures for colon cancer (CC) between 2010 and 2021. Machine learning algorithms were employed to predict CC recurrence, with a focus on demographic, clinicopathological, and laboratory characteristics. A range of evaluation metrics, including AUC (Area Under the Receiver Operating Characteristic), accuracy, recall, precision, and F1 scores, assessed the performance of machine learning algorithms.

RESULTS

Significant risk factors for CC recurrence were identified, including sex, carcinoembryonic antigen (CEA) levels, tumor location, depth, lymphatic and venous invasion, and lymph node involvement. The CatBoost Classifier demonstrated exceptional performance, achieving an AUC of 0.92 and an accuracy of 88 % on the test dataset. Feature importance analysis highlighted the significance of CEA levels, albumin levels, N stage, weight, platelet count, height, neutrophil count, lymphocyte count, and gender in determining recurrence risk.

DISCUSSION

The integration of machine learning into healthcare, exemplified by this study's findings, offers a pathway to personalized patient risk stratification and enhanced clinical decision-making. Early identification of individuals at risk of CC recurrence holds the potential for more effective therapeutic interventions and improved patient outcomes.

CONCLUSION

Machine learning has the potential to revolutionize our approach to CC recurrence prediction, emphasizing the synergy between medical expertise and cutting-edge technology in the fight against cancer. This study represents a vital step toward precision medicine in CC management, showcasing the transformative power of data-driven insights in oncology.

摘要

简介

结直肠癌(CRC)是一个全球性的公共卫生关注点,是全球最常见的恶性肿瘤之一。尽管治疗方式有所进步,但 CRC 复发的问题仍然是一个重大挑战,需要创新的解决方案来进行早期检测和干预。将机器学习应用于肿瘤学提供了一个有前途的途径,可以解决这个问题,提供数据驱动的见解和个性化的护理。

方法

本回顾性研究分析了 2010 年至 2021 年间接受结肠癌(CC)手术治疗的 396 例患者的数据。使用机器学习算法预测 CC 复发,重点关注人口统计学、临床病理和实验室特征。一系列评估指标,包括 AUC(接受者操作特征曲线下的面积)、准确性、召回率、精度和 F1 分数,评估了机器学习算法的性能。

结果

确定了 CC 复发的显著危险因素,包括性别、癌胚抗原(CEA)水平、肿瘤位置、深度、淋巴和静脉侵犯以及淋巴结受累。CatBoost 分类器表现出色,在测试数据集上的 AUC 为 0.92,准确性为 88%。特征重要性分析突出了 CEA 水平、白蛋白水平、N 期、体重、血小板计数、身高、中性粒细胞计数、淋巴细胞计数和性别在确定复发风险方面的重要性。

讨论

机器学习在医疗保健中的应用,如本研究的结果所示,为个性化患者风险分层和增强临床决策提供了途径。早期识别有 CC 复发风险的个体有可能进行更有效的治疗干预并改善患者的结局。

结论

机器学习有可能彻底改变我们预测 CC 复发的方法,强调医学专业知识和癌症领域前沿技术之间的协同作用。本研究代表了 CC 管理精准医学的重要一步,展示了数据驱动的见解在肿瘤学中的变革力量。

相似文献

1
Machine learning for predicting colon cancer recurrence.机器学习预测结肠癌复发。
Surg Oncol. 2024 Jun;54:102079. doi: 10.1016/j.suronc.2024.102079. Epub 2024 Apr 19.
2
Prognostic models for colorectal cancer recurrence using carcinoembryonic antigen measurements.使用癌胚抗原测量值预测结直肠癌复发的模型
Front Oncol. 2024 May 30;14:1368120. doi: 10.3389/fonc.2024.1368120. eCollection 2024.
3
Prediction model of atrial fibrillation recurrence after Cox-Maze IV procedure in patients with chronic valvular disease and atrial fibrillation based on machine learning algorithm.基于机器学习算法的慢性瓣膜病合并心房颤动患者 Cox-Maze IV 术后心房颤动复发预测模型。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Jul 28;48(7):995-1007. doi: 10.11817/j.issn.1672-7347.2023.230018.
4
Machine learning model predicting factors for incisional infection following right hemicolectomy for colon cancer.预测结肠癌右半结肠切除术后切口感染因素的机器学习模型。
BMC Surg. 2024 Oct 1;24(1):279. doi: 10.1186/s12893-024-02543-8.
5
Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment.结肠癌复发和生存的时间依赖性估计:用于辅助治疗和肿瘤学结果评估的临床决策支持系统工具开发
Am Surg. 2014 May;80(5):441-53.
6
Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.基于机器学习方法的甲状腺乳头状癌结构复发预测模型的建立与验证。
BMC Cancer. 2024 Apr 8;24(1):427. doi: 10.1186/s12885-024-12146-4.
7
Development and internal validation of machine learning models for personalized survival predictions in spinal cord glioma patients.机器学习模型在脊髓神经胶质瘤患者个体化生存预测中的开发和内部验证。
Spine J. 2024 Jun;24(6):1065-1076. doi: 10.1016/j.spinee.2024.02.002. Epub 2024 Feb 15.
8
Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.基于机器学习的可解释风险模型识别残胃癌的预后特征:多中心队列研究。
BMC Cancer. 2024 Apr 30;24(1):547. doi: 10.1186/s12885-024-12303-9.
9
Preoperative assessment of lymph node metastasis in Colon Cancer patients using machine learning: a pilot study.使用机器学习对结肠癌患者的淋巴结转移进行术前评估:一项初步研究。
Cancer Imaging. 2020 Apr 25;20(1):30. doi: 10.1186/s40644-020-00308-z.
10
A Prediction Model for Tumor Recurrence in Stage II-III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling.II-III期结直肠癌患者肿瘤复发的预测模型:从机器学习模型到基因组分析
Biomedicines. 2022 Feb 1;10(2):340. doi: 10.3390/biomedicines10020340.